Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

1.

Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients.

Grinyo JM, Saval N, Campistol JM; ICEBERG STUDY Group.

Nephrol Dial Transplant. 2011 Nov;26(11):3750-5. doi: 10.1093/ndt/gfr091. Epub 2011 Apr 7.

2.

Poor compliance with antifungal drug use guidelines by transplant physicians: a framework for educational guidelines and an international consensus on patient safety.

Muñoz P, Rojas L, Cervera C, Garrido G, Fariñas MC, Valerio M, Giannella M, Bouza E; COMIT Study Group.

Clin Transplant. 2012 Jan-Feb;26(1):87-96. doi: 10.1111/j.1399-0012.2011.01405.x. Epub 2011 Feb 7.

PMID:
21299637
3.

Estimation of renal allograft half-life: fact or fiction?

Seron D, Moreso F, Arias M, Campistol JM, Curto J, Hernandez D, Morales JM, Sanchez-Fructuoso A, Abraira V; Spanish Late Allograft Dysfunction Study Group.

Nephrol Dial Transplant. 2011 Sep;26(9):3013-8. doi: 10.1093/ndt/gfq788. Epub 2011 Feb 3. Erratum in: Nephrol Dial Transplant. 2011 Dec;26(12):4153-4. Azancot, M Antonieta [removed]; Cantarell, Carme [removed]; Perelló, Manel [removed]; Torres, Irina B [removed]; Serón, Daniel [removed]; [multiple author names added]; [multiple investigator names added].

4.

Long-term graft function changes in kidney transplant recipients.

Marcén R, Morales JM, Fernández-Rodriguez A, Capdevila L, Pallardó L, Plaza JJ, Cubero JJ, Puig JM, Sanchez-Fructuoso A, Arias M, Alperovich G, Serón D.

NDT Plus. 2010 Jun;3(Suppl_2):ii2-ii8.

5.

Improvement in late renal allograft survival between 1990 and 2002 in Spain: results from a multicentre case-control study.

Moreso F, Alonso A, Gentil MA, González-Molina M, Capdevila L, Marcén R, Pascual J, Serón D; Spanish Late Allograft Dysfunction Study Group.

Transpl Int. 2010 Sep;23(9):907-13. doi: 10.1111/j.1432-2277.2010.01075.x. Epub 2010 Mar 11.

PMID:
20230537
6.

[Renal transplantation with living donors. A critical analysis of surgical procedures based on 40 years of experience].

Vela Navarrete R, Rodríguez Miñón Cifuentes JL, Calahorra Fernández J, González Enguita C, Cabrera J, García Cardoso JV, Castillon Vela I, Plaza JJ.

Actas Urol Esp. 2008 Nov-Dec;32(10):989-94. Spanish.

PMID:
19143290
7.

A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function.

Andrés A, Marcén R, Valdés F, Plumed JS, Solà R, Errasti P, Lauzurica R, Pallardó L, Bustamante J, Amenábar JJ, Plaza JJ, Gómez E, Grinyó JM, Rengel M, Puig JM, Sanz A, Asensio C, Andrés I; NI2A Study Group.

Clin Transplant. 2009 Jan-Feb;23(1):23-32. doi: 10.1111/j.1399-0012.2008.00891.x. Epub 2008 Sep 16.

PMID:
18798851
8.

Severe everolimus-associated pneumonitis in a renal transplant recipient.

Alexandru S, Ortiz A, Baldovi S, Milicua JM, Ruíz-Escribano E, Egido J, Plaza JJ.

Nephrol Dial Transplant. 2008 Oct;23(10):3353-5. doi: 10.1093/ndt/gfn401. Epub 2008 Jul 25.

9.

Inhibitory effect of interleukin-1beta on angiotensin II-induced connective tissue growth factor and type IV collagen production in cultured mesangial cells.

Sánchez-López E, Rodriguez-Vita J, Cartier C, Rupérez M, Esteban V, Carvajal G, Rodrígues-Díez R, Plaza JJ, Egido J, Ruiz-Ortega M.

Am J Physiol Renal Physiol. 2008 Jan;294(1):F149-60. Epub 2007 Nov 7.

10.

Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry.

Ruiz JC, Sánchez A, Rengel M, Beneyto I, Plaza JJ, Zárraga S, Errasti P, Andrés A, Morales JM, Torregrosa JV, Alarcón A, Morey A, Romero R, Fernández A, Díaz JM, Cantarell C; EVERODATA Group.

Transplant Proc. 2007 Sep;39(7):2157-9.

PMID:
17889123
11.

HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways.

Rupérez M, Rodrigues-Díez R, Blanco-Colio LM, Sánchez-López E, Rodríguez-Vita J, Esteban V, Carvajal G, Plaza JJ, Egido J, Ruiz-Ortega M.

Hypertension. 2007 Aug;50(2):377-83. Epub 2007 Jun 25.

12.

The Rho-kinase pathway regulates angiotensin II-induced renal damage.

Rupérez M, Sánchez-López E, Blanco-Colio LM, Esteban V, Rodríguez-Vita J, Plaza JJ, Egido J, Ruiz-Ortega M.

Kidney Int Suppl. 2005 Dec;(99):S39-45.

13.

Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells.

Rodriguez-Vita J, Ruiz-Ortega M, Rupérez M, Esteban V, Sanchez-López E, Plaza JJ, Egido J.

Circ Res. 2005 Jul 22;97(2):125-34. Epub 2005 Jun 23.

14.

Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation.

Fernández-Fresnedo G, Plaza JJ, Sánchez-Plumed J, Sanz-Guajardo A, Palomar-Fontanet R, Arias M.

Nephrol Dial Transplant. 2004 Jun;19 Suppl 3:iii47-51.

15.

Tight blood pressure control decreases apoptosis during renal damage.

Soto K, Gómez-Garre D, Largo R, Gallego-Delgado J, Tejera N, Catalán MP, Ortiz A, Plaza JJ, Alonso C, Egido J.

Kidney Int. 2004 Mar;65(3):811-22.

PMID:
14871401
16.

Angiotensin II increases connective tissue growth factor in the kidney.

Rupérez M, Ruiz-Ortega M, Esteban V, Lorenzo O, Mezzano S, Plaza JJ, Egido J.

Am J Pathol. 2003 Nov;163(5):1937-47.

17.

Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response.

Esteban V, Ruperez M, Vita JR, López ES, Mezzano S, Plaza JJ, Egido J, Ruiz-Ortega M.

Kidney Int Suppl. 2003 Oct;(86):S33-8.

PMID:
12969125
18.

Immunoprophylaxis with Simulect (basiliximab) in kidney transplantation: results from routine clinical practice at 18 kidney transplant units.

Rengel M, Fernández Rodriguez A, Gómez Huertas E, Plaza JJ, Ruiz San Millán JC, Oppenheimer F, Bustamante J, Checa D, Sanchez Plumed JA, García Pérez J, Sanz Guajardo A, Llorente S, Martin Govantes JA, Gentil MA, Gomez Ullate P, Sanchez Guisande D, Puig JM, Fernández C.

Transplant Proc. 2003 Aug;35(5):1691-3.

PMID:
12962760
19.
20.

Role of the renin-angiotensin system in vascular diseases: expanding the field.

Ruiz-Ortega M, Lorenzo O, Rupérez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J.

Hypertension. 2001 Dec 1;38(6):1382-7. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk